Literature DB >> 20974562

SEOM clinical guidelines for the treatment of metastatic breast cancer.

Isabel Alvarez López1, Juan de la Haba Rodríguez, Amparo Ruiz Simón, Meritxell Bellet Ezquerra, Lourdes Calvo Martínez, Laura García Estévez, Álvaro Rodríguez Lescure, Dolores Isla Casado.   

Abstract

Patients with metastatic breast cancer have a wide number of treatment options, including medical, surgical, and supportive care measures. Treatment decisions are based in predictive and prognostic factors and the informed choice of the patients. SEOM has elaborated these guidelines with evidence-based recommendations for the diagnostic work-up, treatment (chemotherapy, endocrine therapy and targeted therapies) and supportive care for the management of these patients.

Entities:  

Mesh：

Year:  2010        PMID： 20974562     DOI： 10.1007/s12094-010-0585-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  14 in total

1.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.

Authors:  H J Burstein; I Kuter; S M Campos; R S Gelman; L Tribou; L M Parker; J Manola; J Younger; U Matulonis; C A Bunnell; A H Partridge; P G Richardson; K Clarke; L N Shulman; E P Winer
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; Nikolaos P Polyzos; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

3.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

4.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Authors:  J G Klijn; R W Blamey; F Boccardo; T Tominaga; L Duchateau; R Sylvester
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Authors:  Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

6.  Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study.

Authors:  E Tomiak; M Piccart; F Mignolet; T Sahmoud; R Paridaens; M Nooy; L Beex; I S Fentiman; A Muller; E van der Schueren; R D Rubens
Journal:  Eur J Cancer       Date:  1996-10       Impact factor: 9.162

7.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

8.  Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

Authors:  Emilio Alba; Miguel Martín; Manuel Ramos; Encarna Adrover; Ana Balil; Carlos Jara; Agustí Barnadas; Antonio Fernández-Aramburo; Pedro Sánchez-Rovira; Margarita Amenedo; Antonio Casado
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

9.  Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.

Authors:  Pier Franco Conte; Valentina Guarneri; Paolo Bruzzi; Tiziana Prochilo; Barbara Salvadori; Angelo Bolognesi; Daniela Aldrighetti; Marco Venturini; Riccardo Rosso; Serafina Mammoliti; Flavio Carnino; Piergiorgio Giannessi; Massimo Costantini; Alfredo Moyano; Editta Baldini
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

10.  Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

Authors:  Stephen Chia; William Gradishar; Louis Mauriac; Jose Bines; Frederic Amant; Miriam Federico; Luis Fein; Gilles Romieu; Aman Buzdar; John F R Robertson; Adam Brufsky; Kurt Possinger; Pamela Rennie; Francisco Sapunar; Elizabeth Lowe; Martine Piccart
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544
View more
  4 in total

1.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

2.  SEOM clinical guidelines for the management of metastatic breast cancer 2013.

Authors:  A Llombart Cussac; J de la Haba Rodríguez; A Ruiz Simón; I Álvarez López; J Cortés Castán
Journal:  Clin Transl Oncol       Date:  2013-10-23       Impact factor: 3.405

Review 3.  RELATIVE EFFECTIVENESS IN BREAST CANCER TREATMENT: A HEALTH PRODUCTION APPROACH.

Authors:  Ruth Puig-Peiro; Anne Mason; Jorge Mestre-Ferrandiz; Adrian Towse; Clare McGrath; Bengt Jonsson
Journal:  Int J Technol Assess Health Care       Date:  2016-01-20       Impact factor: 2.188

4.  Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.

Authors:  Pedro Sánchez-Rovira; Pilar Zamora; Javier Salvador-Bofill; Serafín Morales; Noelia Martínez-Jáñez; Eduardo Martínez-de-Dueñas; Ana Lluch; José Juan Illarramendi; Patricia Gómez-Pardo; Joaquín Gavilá Gregori; Andrés García-Palomo; Jesús García-Mata; Yolanda Fernández; Sonia Del Barco; Ana de Juan; Eva Ciruelos; José Ignacio Chacón; Lourdes Calvo; Agustí Barnadas; Joan Albanell
Journal:  J Drug Assess       Date:  2019-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.